Receptor for gut bacterial toxin linked to colorectal cancer identified, decoy protein blocks it in mice
Researchers have identified claudin-4 as the entry receptor for a bacterially derived toxin associated with colorectal cancer, and designed a decoy protein that blocked it in a mouse model.
Scientists have described the molecular mechanism by which fragilysin — a toxin produced by enterotoxigenic Bacteroides fragilis — gains access to the colonic epithelium and damages its protective barrier. The toxin first binds to claudin-4, a tight-junction protein expressed on colonocyte surfaces, and uses this interaction to breach the mucosal barrier, triggering downstream inflammation and, in animal models, promoting tumour development.
Having identified claudin-4 as the key receptor, the research team designed a decoy protein that mimics the binding site, competitively inhibiting the toxin before it can reach the epithelial surface. In mouse experiments, the decoy successfully blocked toxin activity, reducing both inflammation and colon tumour formation. The findings were reported via ScienceDaily; the primary institution and journal were not specified in the available feed summary.
Enterotoxigenic B. fragilis has been associated with colorectal cancer risk in epidemiological and experimental studies for some years, but the precise initial binding step had not been characterised. Identifying claudin-4 as that first point of attack resolves a long-standing gap in mechanistic understanding and suggests a potential therapeutic target. The decoy-protein approach remains at an early preclinical stage; substantial further work — including safety, specificity, and pharmacokinetic studies — would be required before any translational relevance could be assessed.
Plain-language version
For patients, families, and general readers. Educational only — not medical advice.
Researchers have worked out how a toxin produced by a type of gut bacterium — called Bacteroides fragilis — manages to damage the lining of the colon. The toxin latches onto a protein called claudin-4 on the surface of colon cells, which lets it get inside and cause harm. This bacterium has previously been linked to a higher risk of bowel cancer, though it is one of many factors involved. After identifying this entry point, the team designed a 'decoy' protein that blocked the toxin in laboratory mice, reducing inflammation and tumour growth. This research is at an early stage in animals and does not yet have any direct implications for how bowel cancer is prevented or treated in people. This is an educational summary, not medical advice. If anything here raises questions for you, please speak with your GP or a clinical professional.
Sources
Read the original reporting — these are the public sources this summary draws from.
-
Primary source ScienceDaily · 2026-07-16Scientists finally solved how a common gut bacterium triggers colon cancer